Finally, the authors unveiled an unprecedented immunomodulatorymechanism of action for BR-001 and most likely for EZH2 allostericinhibitors in general.54 Indeed, BR-001resulted in robust upregulation of the CXCL10 chemokine levels incolorectal carcinoma cells that eventually led to CD8+ Tcell recruitment to the tumor in murine models, which might expandthe biological application of this antitumor agent. The gene discussed is EZH2; the disease is neoplasm.